DICE — Dice Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $2.27bn
- $1.72bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.09 | ||
| Price to Tang. Book | 4.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.11% | ||
| Return on Equity | -21.6% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 5.78 | 0.86 | 1.13 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- November 5th, 2014
- Public Since
- July 27th, 2021
- No. of Shareholders
- 27
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 47,730,577
- Address
- 400 East Jamie Court, Suite 300, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.dicetherapeutics.com/
- Phone
- +1 6505661402
- Auditors
- Ernst & Young LLP
Upcoming Events for DICE
Q3 2023 Dice Therapeutics Inc Earnings Release
Similar to DICE
89bio
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Dice Therapeutics share price?
As of Today at 01:07 UTC, shares in Dice Therapeutics are trading at $46.87. This share price information is delayed by 15 minutes.
How has the Dice Therapeutics share price performed this year?
Shares in Dice Therapeutics last closed at $46.87 and the price had moved by +193.67% over the past 365 days. In terms of relative price strength the Dice Therapeutics share price has outperformed the S&P500 Index by +152.11% over the past year.
What are the analyst and broker recommendations for Dice Therapeutics?
The overall consensus recommendation for Dice Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Dice Therapeutics dividend yield?
Dice Therapeutics does not currently pay a dividend.
Does Dice Therapeutics pay a dividend?
Dice Therapeutics does not currently pay a dividend.
When does Dice Therapeutics next pay dividends?
Dice Therapeutics does not currently pay a dividend.
How do I buy Dice Therapeutics shares?
To buy shares in Dice Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dice Therapeutics?
As of the previous close price of $46.87, shares in Dice Therapeutics had a market capitalisation of $2.24bn.
Where are Dice Therapeutics shares listed?
Here are the trading details for Dice Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: DICE
What kind of share is Dice Therapeutics?
Based on an overall assessment of its quality, value and momentum Dice Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dice Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Dice Therapeutics is $49.30. That is 5.18% above the last closing price of $46.87.
Analysts covering Dice Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.57 for the next financial year.
Find out moreWhat is the trend in the Dice Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dice Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +31.31%.
As of the last closing price of $46.87, shares in Dice Therapeutics were trading +39.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dice Therapeutics PE Ratio?
The Dice Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $46.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dice Therapeutics?
We do not have data on Dice Therapeutics' directors